Research Analysts Set Expectations for SABS Q3 Earnings

SAB Biotherapeutics, Inc. (NASDAQ:SABS) – Investment analysts at HC Wainwright lowered their Q3 2026 EPS estimates for shares of SAB Biotherapeutics in a research note issued on Thursday, August 6th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings of ($0.29) per share for the quarter, down from their prior forecast of ($0.26). HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for SAB Biotherapeutics’ current full-year earnings is ($1.21) per share. HC Wainwright also issued estimates for SAB Biotherapeutics’ Q4 2026 earnings at ($0.31) EPS, FY2026 earnings at ($1.21) EPS, FY2027 earnings at ($0.60) EPS, FY2028 earnings at ($0.47) EPS, FY2029 earnings at ($0.48) EPS and FY2030 earnings at ($0.48) EPS.

SAB Biotherapeutics (NASDAQ:SABS) last announced its earnings results on Thursday, August 6th. The company reported ($0.28) EPS for the quarter, hitting analysts’ consensus estimates of ($0.28).

Other research analysts have also recently issued reports about the company. Zacks Research raised SAB Biotherapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, May 11th. Rodman & Renshaw reissued a “buy” rating and issued a $13.00 target price on shares of SAB Biotherapeutics in a report on Monday, May 11th. Chardan Capital raised their target price on shares of SAB Biotherapeutics from $14.00 to $16.00 and gave the stock a “buy” rating in a research note on Wednesday, June 17th. Leerink Partners lifted their price target on shares of SAB Biotherapeutics from $7.00 to $12.00 and gave the company an “outperform” rating in a report on Monday, June 15th. Finally, Jefferies Financial Group initiated coverage on shares of SAB Biotherapeutics in a research report on Wednesday, May 20th. They issued a “buy” rating and a $11.00 price target for the company. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $12.00.

SAB Biotherapeutics Stock Performance

NASDAQ:SABS opened at $3.78 on Monday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.22 and a current ratio of 9.22. The stock has a 50-day simple moving average of $3.69 and a two-hundred day simple moving average of $3.83. The firm has a market capitalization of $343.94 million, a PE ratio of -2.91 and a beta of 0.53. SAB Biotherapeutics has a 52-week low of $1.85 and a 52-week high of $5.15.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Bank of New York Mellon Corp bought a new stake in shares of SAB Biotherapeutics in the second quarter worth about $421,000. Seven Fleet Capital Management LP bought a new position in SAB Biotherapeutics during the first quarter valued at approximately $1,915,000. DV Trading LLC bought a new position in SAB Biotherapeutics during the first quarter valued at approximately $1,532,000. Perceptive Advisors LLC grew its holdings in SAB Biotherapeutics by 700.8% during the 1st quarter. Perceptive Advisors LLC now owns 6,431,743 shares of the company’s stock valued at $24,634,000 after buying an additional 5,628,533 shares in the last quarter. Finally, Bank of America Corp DE grew its holdings in SAB Biotherapeutics by 424.8% during the 1st quarter. Bank of America Corp DE now owns 55,697 shares of the company’s stock valued at $213,000 after buying an additional 45,084 shares in the last quarter. Hedge funds and other institutional investors own 7.82% of the company’s stock.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.